Silver Book Fact

Treatment for hypertension using antihypertensive therapy has generated a benefit-to-cost ratio of at least 6:1.

Cutler, David M., Genia Long, Ernst R. Berndt, Jimmy Royer, Andree-Anne Fournier, Alicia Sasser, and Pierre Cremieux. The Value Of Antihypertensive Drugs: A perspective on medical innovation. Health Affairs. 2007; 26(1): 97-110

Reference

Title
The Value Of Antihypertensive Drugs: A perspective on medical innovation
Publication
Health Affairs
Publisher
Project HOPE
Publication Date
2007
Authors
Cutler, David M., Genia Long, Ernst R. Berndt, Jimmy Royer, Andree-Anne Fournier, Alicia Sasser, and Pierre Cremieux
Volume & Issue
Volume 26, Issue 1
Pages
97-110

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Catheter ablation reduces risk of stroke and death among AFib patients
    Atrial fibrillation patients who underwent catheter ablation had a reduced risk of stroke and death—2.2% of those who had ablation experienced stroke versus 4.7% on medications alone, and 6% died from…  
  • Effectiveness of an oral pharmacologic agent in preventing venous thrombosis
    An oral pharmacologic agent has been demonstrated to be at least as effective as an injectable anticoagulant in the prevention of venous thrombosis following hip replacement.  
  • A major objective is to control blood pressure and preempt primary and secondary stroke. Assessing specific antihypertensive therapies will identify specific treatments that will lower blood pressure.  
  • The greater use of medications and revascularization would provide approximately a 17% reduction in 2 year mortality combined.  
  • Primary angioplasty reduces 30-day mortality risk by 34% to 50%.